United States: Ground Breaking: First Marijuana Based Drug Product Nearing US FDA Approval

An experimental drug derived from cannabis is well poised to
become the first of its kind drug to win approval from the United
States Food and Drug Administration (USFDA). The drug in question
is being developed by GW Pharmaceuticals and is currently known as
Epidiolex. Epidiolex is GW’s lead cannabinoid product candidate
and is a proprietary oral solution of pure plant-derived
cannabidiol, or CBD. GW’s Epidiolex development is initially
concentrating on severe, orphan, early-onset, treatment-resistant
epilepsy syndromes including Dravet syndrome, Lennox-Gastaut
syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile
Spasms (IS)28.

Cannabidiol (CBD) is a cannabinoid prepared from the
Cannabis sativa L. plant and is a new molecular entity. It
is structurally unrelated to other drugs approved for the treatment
of seizures. CBD is currently a Schedule I drug. The exact
mechanism of the anticonvulsant effect of CBD is unknown but does
not appear to involve an interaction with cannabinoid


... read more at: http://www.mondaq.com/unitedstates/x/702950/food+drugs+law/Ground+Breaking+First+Marijuana+Based+Drug+Product+Nearing+US+FDA+Approval